Hummingbird Bioscience
Woodlands · Founded 2014
About Hummingbird Bioscience
Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association, including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas.
Company Facts
- Founded: 2014
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $150.0M
- Funding stage: Late Stage Venture
- Last round: Series C (May 2021)
- Website: hummingbirdbioscience.comen
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/hummingbird-bioscience-26890 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.